{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-020445","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2021-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.932054+00:00","generated_at":"2026-06-29T09:34:54.870390+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biotricity Q1 revenue $1.76M, up 290% YoY, 9th consecutive triple-digit growth quarter","bullets":["Revenue $1.76M for Q1 FY2022, up 290% vs. Q1 FY2021; sequential growth 49%.","Operating expenses $4.2M, up only 17% YoY; R&D spend $590K, up 39%.","Company projects continued revenue growth into FY2023; awaiting FDA approval for Biotres holter product.","Gross margin or net income figures not disclosed; Company remains early-stage."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-020445","json":"https://secwatch.observer/filing/0001493152-21-020445.json","markdown":"https://secwatch.observer/filing/0001493152-21-020445.md","text":"https://secwatch.observer/filing/0001493152-21-020445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315221020445/0001493152-21-020445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315221020445/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T09:34:54.870390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}